ClinicalTrials.gg
TerminatedNCT03302494WAVECREST2Updated Mar 12, 2025Results posted

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

A Phase 3 interventional study of Coherex WaveCrest® Left Atrial Appendage Occlusion System and Watchman® LAA Closure Device in Stroke, sponsored by Coherex Medical. Terminated at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Coherex Medical (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention

Why this study was terminated
Study closed due to device design modification

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Stroke by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Stroke · Johnson & Johnson.

Started
2017
with 1 other
Phase 3
5 of 14
none open now
Registered
11th of 14
by date

Among the 14 studies in Stroke by Johnson & Johnson, this one is one of 2 that started in 2017, is one of 5 in phase 3, and was the 11th registered.

Stroke

8,277 studies on the registry are indexed under Stroke; 2,067 are open to participants now.

Browse Stroke studies →

Open to participants now

None of the 14 studies in Stroke by Johnson & Johnson is open now. The open studies under Stroke, anywhere →

Who these studies take

Of the 1,421 Stroke studies recruiting now, 696 (49%) set no upper age limit and 284 (20%) stop at 75 or younger; 77 take children under 18; 198 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Stroke by Johnson & Johnson as a file.
02

Study summary

The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

Read the detailed description

The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System. Subjects will be randomized in a 1:1 ratio to the Treatment Arm (Coherex WaveCrest LAA occlusion system) or the Control Arm (Boston Scientific's Watchman LAA occlusion system). The trial is designed to demonstrate that safety and effectiveness of the WaveCrest device are non-inferior to the Watchman device.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Non-valvular Atrial Fibrillation
  • Left Atrial Appendage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented evidence of paroxysmal, persistent, or permanent non-valvular atrial fibrillation
  2. At least 18 years of age
  3. Calculated CHADS2 score ≥ 2 or CHA2DS2-VASc score ≥ 3
  4. Indication for warfarin therapy with an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation
  5. Willing and able to comply with post-implant anticoagulation and antiplatelet regimen
  6. Willing to participate in the required follow-up visits and tests
  7. Subject has been informed of the nature of the trial, agrees to its provisions and has provided written as approved by the IRB/EC at the site

Exclusion criteria

Exclusion Criteria:

  1. Atrial fibrillation (AF) due to a reversible cause (e.g. thyrotoxicosis or postoperative)
  2. Known and/or allergy to warfarin, nickel, aspirin, intravenous contrast or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel), which cannot be adequately pre-medicated or desensitized
  3. Conditions other than AF requiring long-term anticoagulation therapy
  4. Contraindications for percutaneous catheterization procedures
  5. Prior surgical LAA occlusion/exclusion or implanted with LAA occlusion device, or any prior attempt of such procedures
  6. Prior percutaneous or surgical closure of a patent foramen ovale or atrial septal defect
  7. Inability or unwillingness to take oral anticoagulation for 45 days post-procedure
  8. (NYHA) Class IV heart failure
  9. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any mechanical valve implant
  10. History of symptomatic carotid, intervertebral, or intracranial artery occlusion or stenosis without revascularization with the exception of known occlusion without symptoms > 6 months
  11. Modified Rankin Scale (mRS) score ≥ 4
  12. Chronic resting heart rate ≥ 110 bpm
  13. Congenital cardiac anomalies requiring cardiac surgery or interventional repair
  14. Stroke or (confirmed by Neurologist) within 60 days prior to enrollment
  15. Myocardial infarction within 60 days prior to enrollment
  16. Sepsis or any infection requiring oral antibiotic therapy within 14 days or intravenous antibiotic therapy within 30 days prior to enrollment
  17. Surgical or interventional cardiovascular and non-cardiovascular procedure including cardioversion within 30 days prior to enrollment or AF ablation within 60 days prior to enrollment or any planned general surgery or interventional procedure within 90 days after enrollment or any planned cardiac surgery.
  18. On renal replacement therapy, serum creatinine > 3.0 mg/dl (265 μmol/L) or calculated \< 25 ml/minute
  19. Thrombocytopenia (\<60,000 /mm3), leucopenia (white blood cell count \< 3,000 cells/mm³), or anemia ( concentration \< 10 grams/deciliter) based on blood work done within 30 days prior to enrollment
  20. Any medical disorder or psychiatric illness that would interfere with successful completion of the trial
  21. Currently participating in an drug trial or another device trial that has not completed the primary endpoint (trials requiring extended follow-up for products that are commercially available are not considered investigational trials). Concurrent enrollment in the ACC LAAO Registry is permitted.
  22. Subject belongs to a vulnerable population (see definition in Appendix I: Acronyms and Definitions)
  23. Any condition that would reduce to less than 2 years
  24. Women of who are, or plan to become pregnant during the time of the trial (method of assessment per physician discretion)

Echocardiographic Exclusion Criteria

  1. \< 30%
  2. Mitral valve stenosis defined as valve area \< 1.5cm2, mean gradient > 6mmHg, or any valve deformity consistent with rheumatic valvular disease
  3. Aortic valve stenosis defined as valve area ≤1.0cm2 or mean gradient >30mmHg
  4. Circumferential pericardial effusion > 10mm or symptomatic pericardial effusion
  5. Evidence of intracardiac thrombus
  6. Cardiac tumor or myxoma
  7. Atrial septal defect that warrants closure
  8. Complex atheroma in the ascending aorta or aortic arch as evidenced by mobile plaque
  9. Left Atrial Appendage size and shape are unsuitable for closure with a WaveCrest or Watchman device
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    WaveCrest

    WaveCrest left atrial appendage occluder

    Device: Coherex WaveCrest® Left Atrial Appendage Occlusion System

  • Active comparator
    Watchman (control)

    Watchman left atrial appendage closure device

    Device: Watchman® LAA Closure Device

Interventions

  • DeviceCoherex WaveCrest® Left Atrial Appendage Occlusion System

    Percutaneous left atrial appendage closure

  • DeviceWatchman® LAA Closure Device

    Percutaeous left atrial appendage closure

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Composite of All Cause Death, Procedure or Device Related Complications Requiring Percutaneous or Surgical Intervention or Major Bleeding

    The primary safety outcome was the composite of death from any cause (all-cause mortality), procedure or device related complications requiring percutaneous or surgical intervention through 45 days post procedure or major bleeding throughout the duration of the trial. The analysis was based on sponsor assessment of adverse events data. Baseline was defined as 90 day prior to treatment or 90 days prior to randomization; baseline assessments could occur on the day of implant.

    Time frame: All death, procedure- or device-related complications requiring percutaneous or surgical intervention: From baseline up to 45 days; major bleeding: From baseline up to 5 years 11 months

  2. Percentage of Participants With Composite of Ischemic Stroke or Systemic Embolism at 24 Months

    Percentage of participants with composite of ischemic stroke or systemic embolism at 24 months was reported.

    Time frame: At 24 months

Secondary outcomes

  1. Percentage of Participants With Ischemic Stroke or Systemic Embolism With the WAVECREST Device in Comparison to the CHADS2 and CHA2DS2-VASc Imputed Risk of Ischemic Stroke or Systemic Embolism in the Absence of Anticoagulant Therapy

    CHADS2 (congestive heart failure, hypertension, age \>=75 years (yrs), prior Stroke/transient ischemic attack (TIA)/Thromboembolism) and CHA2DS2-VASc scores (Vascular disease, Age 65- 74 yrs, female Sex) were developed to identify non-valvular atrial fibrillation (AF) participants at an elevated risk for ischemic stroke. CHADS2 score assign 1 point: congestive heart failure, hypertension, age \>= 75 yrs, diabetes mellitus; 2 points: prior stroke/TIA/thromboembolism. CHADS2 score ranges from 0 to 6. Higher scores indicated higher risk for ischemic strokes. CHA2DS2-VASc Score assign 1 point for each following risk factors: congestive heart failure, hypertension (blood pressure consistently above 140/90), diabetes mellitus, vascular disease, age 65 to74 yrs, female and assigned 2 points for age \>=75 yrs and prior stroke or TIA or thromboembolism each. Overall score ranged from 0 to a 9, with lower scores indicated lower risk and higher scores indicated higher risk for ischemic strokes.

    Time frame: At 45 days

  2. Percentage of Participants With Left Atrial Appendage (LAA) Closure

    Percentage of participants with LAA closure, defined as a gap of \<= 5 millimetre (mm) at the 45-day visit as assessed by transesophageal echocardiogram (TEE) was reported.

    Time frame: At 45 days

07

Results

Posted Mar 12, 2025

Participant flow

Analysis population included participants greater than or equal to (\>=) 18 years old diagnosed with non-valvular atrial fibrillation and a CHADS2 score \>= 2 or a CHA2DS2-VASc score \>= 3 who had an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation.

Participant flow — Overall Study
MilestoneGroup 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
Started715458
Treated715256
Completed613
Not completed655355
Withdrew: Other746
Withdrew: Withdrawal by subject1029
Withdrew: Study terminated by sponsor322930
Withdrew: Physician decision101
Withdrew: Lost to follow-up133
Withdrew: Death13114
Withdrew: Adverse event120
Withdrew: Randomized but not treated and discontinued during study hold022

Outcome measures

PrimaryPercentage of Participants With Composite of All Cause Death, Procedure or Device Related Complications Requiring Percutaneous or Surgical Intervention or Major Bleeding

The primary safety outcome was the composite of death from any cause (all-cause mortality), procedure or device related complications requiring percutaneous or surgical intervention through 45 days post procedure or major bleeding throughout the duration of the trial. The analysis was based on sponsor assessment of adverse events data. Baseline was defined as 90 day prior to treatment or 90 days prior to randomization; baseline assessments could occur on the day of implant.

Time frame:
All death, procedure- or device-related complications requiring percutaneous or surgical intervention: From baseline up to 45 days; major bleeding: From baseline up to 5 years 11 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite of All Cause Death, Procedure or Device Related Complications Requiring Percutaneous or Surgical Intervention or Major Bleeding
Percentage of participantsGroup 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
Percentage of Participants With Composite of All Cause Death, Procedure or Device Related Complications Requiring Percutaneous or Surgical Intervention or Major Bleeding47.89 (35.9 to 60.1)32.69 (20.3 to 47.1)17.86 (8.9 to 30.4)
PrimaryPercentage of Participants With Composite of Ischemic Stroke or Systemic Embolism at 24 Months

Percentage of participants with composite of ischemic stroke or systemic embolism at 24 months was reported.

Time frame:
At 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite of Ischemic Stroke or Systemic Embolism at 24 Months
Percentage of participantsGroup 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
Percentage of Participants With Composite of Ischemic Stroke or Systemic Embolism at 24 Months4.23 (0.9 to 11.9)3.85 (0.5 to 13.2)5.36 (1.1 to 14.9)
SecondaryPercentage of Participants With Ischemic Stroke or Systemic Embolism With the WAVECREST Device in Comparison to the CHADS2 and CHA2DS2-VASc Imputed Risk of Ischemic Stroke or Systemic Embolism in the Absence of Anticoagulant Therapy

CHADS2 (congestive heart failure, hypertension, age \>=75 years (yrs), prior Stroke/transient ischemic attack (TIA)/Thromboembolism) and CHA2DS2-VASc scores (Vascular disease, Age 65- 74 yrs, female Sex) were developed to identify non-valvular atrial fibrillation (AF) participants at an elevated risk for ischemic stroke. CHADS2 score assign 1 point: congestive heart failure, hypertension, age \>= 75 yrs, diabetes mellitus; 2 points: prior stroke/TIA/thromboembolism. CHADS2 score ranges from 0 to 6. Higher scores indicated higher risk for ischemic strokes. CHA2DS2-VASc Score assign 1 point for each following risk factors: congestive heart failure, hypertension (blood pressure consistently above 140/90), diabetes mellitus, vascular disease, age 65 to74 yrs, female and assigned 2 points for age \>=75 yrs and prior stroke or TIA or thromboembolism each. Overall score ranged from 0 to a 9, with lower scores indicated lower risk and higher scores indicated higher risk for ischemic strokes.

Time frame:
At 45 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Ischemic Stroke or Systemic Embolism With the WAVECREST Device in Comparison to the CHADS2 and CHA2DS2-VASc Imputed Risk of Ischemic Stroke or Systemic Embolism in the Absence of Anticoagulant Therapy
Percentage of participantsGroup 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
ischemic strokes4.233.855.36
systemic embolisms000
SecondaryPercentage of Participants With Left Atrial Appendage (LAA) Closure

Percentage of participants with LAA closure, defined as a gap of \<= 5 millimetre (mm) at the 45-day visit as assessed by transesophageal echocardiogram (TEE) was reported.

Time frame:
At 45 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Left Atrial Appendage (LAA) Closure
Percentage of participantsGroup 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
Percentage of Participants With Left Atrial Appendage (LAA) Closure100.0100.0100.0

Adverse events

Collected over Baseline up to 5 years 11 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (WaveCrest Roll-In):15/71 (21.1%)50/71 (70.4%)63/71 (88.7%)
Group 2 (WaveCrest Randomized)13/52 (25%)42/52 (80.8%)51/52 (98.1%)
Group 3 (Watchman Randomized)4/56 (7.1%)39/56 (69.6%)48/56 (85.7%)
Most frequent serious events
Showing 10 of 247
Most frequent serious events
EventGroup 1 (WaveCrest Roll-In):Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
Atrial fibrillationCardiac disorders11/717/525/56
Pericardial effusionCardiac disorders9/712/521/56
Acute kidney injuryRenal and urinary disorders9/711/520/56
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/713/527/56
Cardiac failure congestiveCardiac disorders6/716/526/56
PneumoniaInfections and infestations7/716/526/56
AnaemiaBlood and lymphatic system disorders7/712/523/56
Gastrointestinal haemorrhageGastrointestinal disorders7/714/523/56
Urinary tract infectionInfections and infestations3/714/523/56
OsteoarthritisMusculoskeletal and connective tissue disorders1/714/522/56
Most frequent other events
Showing 10 of 29
Most frequent other events
EventGroup 1 (WaveCrest Roll-In):Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)
Metabolism and nutrition disordersMetabolism and nutrition disorders14/7113/5210/56
Gastrointestinal disordersGastrointestinal disorders15/7110/5213/56
Pericardial effusionCardiac disorders11/7112/5212/56
Atrial fibrillationCardiac disorders13/718/524/56
Corona virus infectionInfections and infestations9/719/525/56
Urinary tract infectionInfections and infestations10/715/529/56
DyspnoeaRespiratory, thoracic and mediastinal disorders11/716/528/56
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders11/714/525/56
Acute kidney injuryRenal and urinary disorders9/712/526/56
Chest painGeneral disorders8/715/527/56

Baseline characteristics

The modified intention-to-treat (mITT) analysis set consisted of all randomized participants who had vascular access attempted for the implant procedure of the intended left atrial appendage (LAA) occlusion device.

Age, Continuous
Age, Continuous(years)Group 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)Total
Mean72.0 ± 9.6475.9 ± 6.4376.0 ± 5.6974.4 ± 7.88
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)Total
Female32212073
Male393136106
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1 (WaveCrest Roll-In)Group 2 (WaveCrest Randomized)Group 3 (Watchman Randomized)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1124
White695153173
More than one race0011
Unknown or Not Reported1001
08

Study locations

25 sites
  • Grandview Medical Center
    Birmingham, Alabama 35243, United States
  • Dignity Health Mercy Gilbert Medical Center
    Chandler, Arizona 85224, United States
  • Pacific Heart Institute / St. John's Health Center
    Los Angeles, California 90033, United States
  • Medstar Heart and Vascular Institute - Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • St. Vincent's Medical Center
    Jacksonville, Florida 32204, United States
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • Wellstar Kennestone
    Marietta, Georgia 30060, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • MedStar Union Memorial Hospital
    Baltimore, Maryland 21218, United States
  • Marquette General Hospital
    Marquette, Michigan 49855, United States
  • Munson Medical Center
    Traverse City, Michigan 49684, United States
  • Cardiology Associates Research, LLC
    Tupelo, Mississippi 38801, United States
  • Northwell Health
    Bay Shore, New York 11706, United States
  • New York University- NYU Langone Cardiac
    New York, New York 10016, United States
  • New York University
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • UPMC Pinnacle Health Cardiovascular Institute
    Harrisburg, Pennsylvania 17104, United States
  • Texas Cardiac Arrhythmia Research Foundation
    Austin, Texas 78705, United States
  • Baylor Scott & White All Saints Medical Center
    Fort Worth, Texas 76104, United States
  • Heart Hospital Baylor Plano (Baylor Research Institute)
    Plano, Texas 75093, United States
  • Christus Trinity Clinic Research
    Tyler, Texas 75702, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Monash Health
    Melbourne, Australia
  • St. Vincent's Hospital
    Sydney, 2023, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Dec 2023, 71 months.

Results were first posted in Mar 2025, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 5, 2017
StartActual
Dec 27, 2017
Primary completionActual
Dec 21, 2023
CompletionActual
Dec 21, 2023
Results first posted
Mar 12, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03302494
Lead sponsor
Coherex Medical
Responsible party
Sponsor
First posted
Oct 5, 2017
Start date
Dec 27, 2017
Primary completion
Dec 21, 2023
Completion
Dec 21, 2023
Results posted
Mar 12, 2025
Last update
Mar 12, 2025

Study contacts

Vivek Reddy, MD
study chair · MOUNT SINAI HOSPITAL
Gregg Stone, MD
study chair · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion